Dermoscopy – A Third Eye For Dermatologist

The use of this technique provides a valuable aid in diagnosing pigmented skin lesions; hair disorders, inflammatory and others skin diseases. Dermatoscopic evaluation shows specific or non specific pattern of diseases which can be co-related with clinical history and examination to reach final diagnosis.

Need for dermatoscope is not a novel approach in dermatology. Hand lens has been used by dermatologist from hundreds of years for the same purpose. Dermatosope has advantage for having image proof with better resolution thus becomes the essential instrument in dermatology clinic. Commercially different types of dermatoscope are available and one has to be wise in purchasing the device.

Types of device: – (a) The dermatoscope: – It is the simplest and best-recognized piece of equipment used to perform a dermoscopy examination. It is easy to operate with minimal technical support.  The price varies according to manufacturing companies, types of device, power of lens used and use of assisting device. A dermatoscope can be connected with anything among TV monitor, computer, camera, mobile or USB device.  Power of lens varies among dermatoscope, 50-200x magnification is sufficient enough for routine clinical practice.

Components: – Achromatic lens, Inbuilt illuminating system, Power supply, image analyzer.

 (b) Stereomicroscope: – It allows an accurate binocular observation with different magnifications (X6-80). The illumination system includes a halogen lamp (12 V/50 W). The stereomicroscope is expensive, large and bulky. It is not indicted for routine clinical practice and only advantage is of better visualisation then dermatoscope.

(c) Videodermatoscope

The videodermatoscope include a polarized or nonpolarized video probe that transmits images of the skin lesion to a color monitor.

Nonpolarized v/s polarized light.

The polarized system allows a better visualization of vessels and red areas. Nonpolarized dermoscopy requires the application of a liquid or a gel in the interface between the instrument and the skin surface. Furthermore, the study of vascular pattern may be compromised by excessive pressure of the instrument resulting in compression of vessels. Thus, vascular patterns cannot properly be examined in their real shape. On the other hand, structures such as pseudocysts, multiple gray-blue dots and blue-white veil are more accurately evaluated by non polarized dermoscopy.

Indications:

1.      Hair and scalp disorder- Dermatoscopy or trichoscopy helps in visualisation of hair shaft, texture, cuticle, hair follicle opening, cutaneous microvessels,  intrafollicular, interfollicular and perifollicular skin changes. Congenital hair shaft abnormalities like as monilethrix, trichorrhexis nodosa, trichorrhexis invaginata, pili torti or pili annulati are more evident on dermoscopy. Acquired hair shaft abnormalities;- micro-exclamation mark hairs, tapered hairs and tulip hairs (in alopecia areata and trichotillomania), regrowing upright or pigtail hairs (in various diseases), comma hair or corckscrew hairs (in tinea capitis). Both scarring and non scarring allopecia can be easly differentiated and at times reduce the need for scalp biopsies.  Trichoscopy also allows use for assessing the number of hairs in one follicular unit. In healthy individuals 2-3 hairs emerge from one follicular unit. The number is decreased in non-cicatricial alopecia and increased above 4 in tufted folliculitis, folliculitis decalvans or lichen planopilaris.

Dermoscopy can also be used for prognosis of scalp disorders following treatment. Hair shaft number per follicle, thickness of hair and interfolliclar distance, all can be measured and compared further with the use of dermatoscope.

2.   Pigmentory disorder:–  Dermoscopy helps in visualisation of by specific or nonspecific pattern of pigmented skin disorder. The identification of specific diagnostic patterns related to the distribution of colors and dermoscopy structures can better suggest a malignant or benign pigmented skin lesion. There are specific and non-specific guide criteria for pigmentory skin disorder. Specific guide criteria are further classified as primary and secondary criteria.

Primary guide criteria: – pigment network, pseudopigmneted network, radial streaming and pseudopodes, pigmented globules.

Fig 3. A. pigment network (melanoma), B. radial streaming (melanoma),

C. Pseudopodes (melanoma) , D. pigmented globules (melanocytic neavus).

(adapted from [4]).

Secondary criteria: – Pigmented dots, blue-white veil, blue grey areas, steel blue areas, depigmnetation.

Secondary criteria: – Pigmented dots, blue-white veil, blue grey areas, steel blue areas, depigmnetation.

Conclusion:- 

Among all the dermatological disorder, majority of them rely on careful observation and examination with naked eye. Dermatoscope enhance the optical resolution with image proof of skin disorder thus helps in diagnosing and  further evolution of skin disorder. Several dermatoscopes are available in market and choice should be made on power of lens, image quality, polarized and/or nonpolarized light, assisting device like mobile, computer, and camera. Many research article been published recently and has become area of interest for dermatologist. More research is required for the best use of dermoscope.

1.     Sar-Pomian M, Kurzeja M, Rudnicka L, Olszewska M, The value of trichoscopy in the differential diagnosis of scalp lesions in pemphigus vulgaris and pemphigus foliaceus. An Bras Dermatol. 2014;89(6):1007-12.

2.      Francesco Lacarrubba, Anna Elisa Verzì and Giuseppe Micali*. Dermatoscopy and Video Dermatoscopy in the Diagnosis and Therapeutic Monitoring of Plaque Psoriasis: A Review.  2014; 1(6).

3.     Lidia Rudnicka, Małgorzata Olszewska, Adriana Rakowska, Monika Slowinska. Trichoscopy update 2011. J Dermatol Case Rep 2011 4, pp 82-88.

4.     Ignazio Stanganelli, Maria Antonietta Pizzichetta, Dermoscopy; www.http://emedicine.medscape.com/article/1130783-overview;

Low Level Laser Therapy For Management Of Hair Loss

•       LLLT was discovered serendipitously in the 1960s when mice irradiated with a low fluence red laser grew hair.

•       It traditionally uses infrared rays which are non-invasive and cause non-thermal biostimulation of the hair.

•       Light source used here is an LED device or light energy below a specific energy threshold with a specific wavelength

•       Since it does not produce heat (cold laser), the therapy is safe and does not cause a burn.

•       Various lasers that have been tried for hair loss management include- Excimer (308nm) helium, neon (632nm) and fractional erbium glass laser (1550nm)

•       LLLT uses devices with diode that emit red light (630-670nm). It is available in the form of :-

  1. Hoods / overhead panels
  2. Bonnet or laser head caps
  3. Hand held device

HOW DOES LLLT WORK ?

  1. LLLT increases the blood flow to the scalp and stimulates the metabolism in telogen and catagen hair.
  2. LLLT is proposed to act by stimulation of mitochondria to produce more ATP and cyclic AMP, with activation of response to oxidative stress, displacing nitric oxide from the cells and allowing more oxygen to enter. Released nitric oxide also induces vasodilatation and improves blood flow to the hair roots.
  3. Induction of transcription factors such as nuclear factor kappa B and hypoxia-inducible factor-1 occurs which in return causes protein synthesis that triggers further effects down-stream, such as increased cell proliferation and migration, alteration in the levels of cytokines, growth factors and inflammatory mediators, and increased tissue oxygenation. (6-8)
  4. Weiss and coworkers, by using RT-PCR and microarray analysis, demonstrated that depending on the treatment parameters, LLLT modulates 5-α reductase expression (which converts testosterone into DHT), alters vascular endothelial growth factor gene expression as wells as matrix metalloproteinase (MMP-2) which have significant roles in hair follicle growth. (9)
  5. LED uses broader beam of light to cover wider area of the scalp.
  6. LLLT has been demonstrated to modulate inflammatory processes and immunological responses, which may also have an effect in hair regrowth thus it may also be used in hair transplant patients post operatively to promote wound healing and expedite hair growth.

BENEFITS OF LASER THERAPY

  • Effective in both men and women
  • Can be used in a variety of non-scarring alopecias- AA, AGA, alopecia occurring after chemotherapy.
  • Non-surgical and non-invasive method of hair restoration.
  • No major adverse effects reported
  • Painless, no chances of burns.
  • Relatively inexpensive
  • Minimal time commitment
  • Portable device

REFERENCES:

  1. Kalia S, Lui H. Utilizing electromagnetic radiation for hair growth: a critical review of phototrichogenesis. Dermatol Clin. 2013 Jan;31(1):193-200.
  2. McElwee KJ and Shapiro J. Promising Therapies for treating and/or preventing androgenic alopecia . Skin Therapy Lett. 2012 Jun; 17(6):1-4.
  3. Schweiger ES, Boychenko O, Bernstein RM. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J Drugs Dermatol. 2010 Nov;9(11):1412-9.
  4. Castex-Rizzi N, Lachgar S, Charveron M, Gall Y. Implication of VEGF, steroid hormones and neuropeptides in hair follicle cell responses. Ann Dermatol Venereol. 2002;129(5 Pt 2):783–786.
  5. Weiss R, McDaniel DH, Geronemus RG, Weiss M. LED photomodulation induced hair growth stimulation. 2005;36(S17):27.
  6. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107:409–417.
  7. Yamazaki M, Tsuboi R, Lee YR, Ishidoh K, Mitsui S, Ogawa H. Hair cycle-dependent expression of hepatocyte growth factor (HGF) activator, other proteinases, and proteinase inhibitors correlates with the expression of HGF in rat hair follicles. J Investig Dermatol Symp Proc. 1999;4(3):312–315.
  8. Low level laser (light) therapy (LLLT) for treatment of hair loss: Laser Surg Med: 2014,Feb; 46(2): 144-151

Plant Derived Anti-Androgens

Anti-androgen medications are used to treat signs of hyperandrogenism, including skin and hair disorders like acne, seborrhoea,  hirsutism,  androgenic alopecia and hidradenitis suppurativa. Anti-androgen therapy may bock androgen receptor, reduce adrenal androgen production, reduce ovarian androgen production, reduce pituitary production of prolactin, inhibit 5-alpha reductase or reduce insulin resistance.

Current Anti-Androgen Therapies

Cyproterone acetate is a synthetically derived steroid that acts as a potent anti-androgen. It also possesses progestational properties and can be used to assist conception in subfertile females.  Flutamide/nilutamide/bicalutamide are all non-steroidal, pure anti-androgens. Bicalutamide is the newest agent and has the fewest side effects. Finasteride/dutasteride are inhibitors of 5-alpha reductase, an enzyme that prevents the conversion of testosterone into the active form ihydrotestosterone (DHT). They are specific anti-androgens in that they only counteract the effects of testosterone and not other androgens. Spironolactone, a synthetic 17-spironolactone corticosteroid, is commonly used as a competitive aldosterone antagonist and acts as a potassium sparing diuretic. It used to treat low-renin hypertension, hypokalemia, and Conn’s syndrome. It has recognized anti-androgen effects. Ketoconazole is a derivative of imidazole that is used as a broad spectrum antifungal agent. Recognized effects are severe liver damage, but there is also an adrenolytic function. Ketoconazole reduces androgen production in the testes and the adrenal glands. It is a relatively weak anti-androgen, but is used with good effect in patients with Cushing’s syndrome.

Herbal Anti-Androgens

There is an ever-increasing demand for complementary therapies, or those that are perceived as being more natural. The presence of anti-androgenic chemicals in plants, herbs, and foodstuffs provides an alternative to modern synthetic pharmaceuticals. It is also commonly believed that there are fewer adverse effects of such alternative therapies. While this group of treatments may be slow to find favor and may not be used first line, it does at least appear to be more acceptable to patients because of its perceived more natural origins (29). Herbal remedies to block testosterone come in a variety of forms, including capsules, powders, teas and tinctures, or alcohol extracts.

Saw Palmetto (Serenoa repens)

Saw palmetto is a small palm tree native to eastern regions of the United States. Its extract is believed to be a highly effective anti-androgen as it contains phytoesterols. This has been the subject of a great deal of research with regards to the treatment of BPH (19, 20), androgenic alopecia (21), and PCOS (22). In the context of BPH, there have been 2 reasonably sized clinical trials that found that saw palmetto extract use showed no difference in comparison to placebo (23, 24). In meta-analyses, it has been shown to be safe and effective in mild to moderate BPH when compared to finasteride, tamsulosin, and placebo (25, 26).

Saw palmetto is likely safe for most people. Side effects are usually mild. Some people have reported dizziness, headache, nausea, vomiting, constipation, and diarrhea. Saw palmetto is likely unsafe when used during pregnancy or breast-feeding. Saw palmetto might decrease the effects of estrogen in the body, hence taking it along with birth control pills might decrease the effectiveness of birth control pills. It may slow blood clotting and increase the chances of bruising and bleeding. It should be stopped at least 2 weeks before a scheduled surgery. Established dosages for BPH is 160 mg twice daily or 320 mg once daily and for androgenic alopecia is 200 mg twice daily combined with beta-sitosterol 50 mg twice daily.

Reishi mushrooms (Ganoderma lucidum)

Red reishi, commonly known as LingZhi in Chinese, is a mushroom thought to have many health benefits. In a research study exploring the anti-androgenic effects of 20 species of mushrooms, reishi mushrooms had the strongest action in inhibiting testosterone (3). That study found that reishi mushrooms significantly reduced levels of 5-alpha reductase, preventing conversion of testosterone into the more potent DHT. Oral reishi extract is possibly safe for up to one year, but possibly unsafe when taken in a powdered form for more than one month as it might be hepatotoxic. Reishi can also cause other side effects including dryness of the mouth, throat, and nasal area along with itchiness, stomach upset, nosebleeds, dermatitis and bloody stools. There is not enough reliable information about the safety of taking reishi

mushroom if you are pregnant or breast feeding. Reishi mushroom might decrease blood pressure. High doses of reishi mushroom might increase the risk of bleeding in some people with certain bleeding disorders. Anticoagulant / antiplatelet drugs and antihypertensives interact with this medication. Stop using reishi at least 2 weeks before a scheduled surgery.

White Peony (Paeonia lactiflora)

Chinese peony is a widely grown ornamental plant with several hundred selected cultivars. Many of the cultivars have double flowers with the stamens modified into additional petals. White peony has been important in traditional Chinese medicine and has been shown to affect human androgen levels in vitro. In a 1991 study in the American Journal of Chinese Medicine Takeuchi et al described the effects of paeoniflorin, a compound found in white peony that inhibited the production of testosterone and promoted the activity of aromatase, which converts testosterone into estrogen (7). To date, there have been no studies that translate or explore the clinical effects. Peony has been used safely for up to 4 weeks. It can cause stomach upset and dermatitis. Peony is possibly unsafe when taken by mouth during pregnancy and lactation. Some developing research suggests that peony can cause uterine contractions. Peony may increase the risk of bleeding in some people with certain bleeding disorders. Anticoagulant / antiplatelet drugs and phenytoin (it may decrease the amount of phenytoin) interact with this medication.  It has to be stopped at least 2 weeks before a scheduled surgery.

Chaste Tree (Vitex agnus-castus)

Chaste tree (or chasteberry) is a native of the Mediterranean region and is traditionally used to correct hormone imbalances. In ancient times, it was believed to be an anaphrodisiac, hence the name chaste tree. Clinical studies have demonstrated effectiveness of medications produced from extract of the plant in the management of premenstrual syndrome (PMS) and cyclical mastalgia (14). The mechanism of action is presumed to be via dopaminergic effects resulting in changes of prolactin secretion from the anterior pituitary. At low doses, it blocks the activation of D2 receptors in the brain by competitive binding, causing a slight increase in prolactin release. In higher concentrations, the binding activity is sufficient to reduce the release of prolactin (15). Reduction in prolactin levels affects FSH and estrogen levels in females and testosterone levels in men. There is as yet no information regarding its efficacy in endocrine disease states such as PCOS, however, one small-scale study has demonstrated this prolactin reducing effect in a group of healthy males, and the implication is that it could be of use in mild hyperprolactinemia (16, 17). One could also theorize that it could be refined for use as a male contraceptive, because testosterone reduction should reduce libido and sperm production. This topic is further explored in a review by Grant & Anawalt (18). Vitex agnus-castus  is likely safe for most people when taken by mouth and applied to skin. Uncommon side effects include upset stomach, nausea, itching, rash, headaches, acne, trouble sleeping, and weight gain. Use during pregnancy or breast-feeding is possibly unsafe. It should be avoided in hormone-sensitive condition such as endometriosis; uterine fibroids; or cancer of the breast, uterus, or ovaries, during IVF procedures. It may decrease effectiveness of contraceptive pills. It has dopamine agonist like actions, hence might affect therapy for Parkinson’s disease, Schizophrenia or other psychotic disorders. Crude herb extracts are typically used in doses of 20-240 mg per day up to 1800 mg per day in 2-3 divided doses.

Green Tea (Camellia sinensis)

In addition to supporting the cardiovascular system and somewhat reducing the risk of cancer and type 2 diabetes (8), green tea may also have an important anti-ndrogen effect because it contains epigallocatechins, which inhibit the 5-alpha-reductase conversion of normal testosterone into DHT. As previously noted, this anti-androgen mechanism may help to reduce the risk of BPH, acne, and baldness. As yet, no randomized controlled trials of green tea for these androgen dependent conditions have been conducted. Green tea is likely safe for most adults when consumed in moderate amounts. Green tea extract is possibly safe for most people when taken by mouth or applied to the skin for a short time. In some people, green tea can cause stomach upset and constipation. Green tea extracts have been reported to cause hepatotoxicity in rare cases. Drinking more than five cups per day is possibly unsafe because of the caffeine. These side effects can range from ild to serious and include headache, nervousness, sleep problems, vomiting, diarrhea, irritability, irregular heartbeat, tremor, heartburn, dizziness, ringing in the ears, convulsions, and confusion. Green tea seems to reduce the absorption of iron from food. The fatal dose of caffeine in green tea is estimated to be 10-14 grams (150-200 mg per kilogram).  During pregnancy and lactation about 2 cups per day is possibly safe. It may make anemia worse, the caffeine in it may affect nxiety disorders, bleeding disorders, heart conditions, diabetes, irritable bowel syndrome, glaucoma, blood pressure. Some reports have linked it to osteoporosis (caffeine increases amount of urinary calcium excretion) and hepatic diseases. It interacts with stimulant drugs, some quinolone antibiotics, birth control pills, antidepressants, nticoagulants, nicotine, theophylline, verapamil etc. Doses of green tea vary significantly, but usually range between 1-10 cups daily (three cups approximately rovides 240-320 mg of the active ingredients, polyphenols). To make tea, people typically use 1 teaspoon of tea leaves in 8 ounces boiling water.

Spearmint (Mentha spicata [Labiatae]) 

Spearmint, usually taken in the form of tea, has been thought for many years to have testosterone reducing properties. It is commonly used in Middle Eastern regions as an herbal remedy for hirsutism in females. Its anti-androgenic properties reduce the level of free testosterone in the blood, while leaving total testosterone and DHEAS unaffected, as demonstrated in a study from Turkey by Akdogan and colleagues, in which 21 females with hirsutism (12 with polycystic vary syndrome and 9 with idiopathic hirsutism) drank a cup of herbal tea steeped with M. spicata twice daily for 5 days during the follicular phases of their menstrual cycles. After treatment with the spearmint tea, the patients had significant decreases in free testosterone with increases in luteinizing hormone, follicle-stimulating hormone, and estradiol (9). There were no significant decreases in total testosterone or DHEAS levels. This study was followed by a randomized clinical trial by Grant (10), which showed that drinking spearmint tea twice daily for 30 days (vs. chamomile tea, which was used as a control) significantly reduced plasma levels of gonadotropins and androgens in patients with hirsutism associated with polycystic ovarian syndrome. There was a significant change in patients’ self-reported dermatology-related quality of life indices, but no objective change on the Ferriman-Gallwey scale. It is possible that sustained daily use of spearmint tea could result in further abatement of hirsutism. Avoid using in large amounts of spearmint during pregnancy and lactation. In theory, using large amounts of spearmint tea might worsen kidney and liver disorders.

Licorice (Glycyrrhiza glabra)

Licorice is a flavorful substance that has been used in food and medicinal remedies for thousands of years. It is also known as “sweet root,” licorice root contains a compound that is about 50 times sweeter than sugar. It has been used in both Eastern and Western medicine to treat a variety of illnesses ranging from the common cold to liver disease. Licorice affects the endocrine system because it contains isoflavones (phytoestrogens), which are chemicals found in plants that may mimic the effects of estrogen and relieve menopausal symptoms and menstrual disorders. Licorice may also reduce testosterone levels, which can contribute to hirsutism in women. A small clinical trial published in 2004 by Armanini and colleagues found that licorice root significantly decreases testosterone levels in healthy female volunteers. Women taking daily licorice root experienced a drop in total testosterone levels after 1 month and testosterone levels returned to normal after discontinuation. It is unclear as to whether licorice root affects free testosterone levels (4). The endocrine effect is thought to be due to phytoestrogens and other chemicals found in licorice root, including the steroid glycyrrhizin and glycyrrhetic acid, which also have a weak anti-androgen effect (5, 6). Consuming licorice daily in large doses for more than 4 weeks may cause side effects. In Pregnancy and breast-feeding it is not safe to take oral licorice. It can raise blood pressure, can decrease potassium levels in the blood, can cause water retention hence should be used with caution in heart disease, hypertension, hypertonia, hypokalemia, kidney disease. It should be avoided in hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids. It may cause loss of libido in men and also worsen erectile dysfunction (ED). It could interact with many drugs like digoxin, OCPs, anticoagulants, ethacrynic acid, medications metabolized by the liver, antihypertensive drugs, corticosteroids, diuretics, etc.

Black Cohosh (Actaea racemosa)

Black cohosh (Actaea racemosa) is a plant of the buttercup family. Extracts from these plants are thought to possess analgesic, sedative, and anti-inflammatory properties. Black cohosh preparations (tinctures or tablets of dried materials) are used to treat symptoms associated with menopause, such as hot flashes, although the efficacy has been questioned (11). The inhibitory effects of black cohosh extracts (Cimicifuga syn. Actaea racemosa L.) on the proliferation of human breast ancer cells has been reported recently (12), and Hostsanka. et al (13) have examined the plant’s effects on prostate cancer, another androgen hormone-dependent, pidemiologically important tumor. In that study, the inhibitory effect of an isopropanolic extract of black cohosh (iCR) on cell growth in androgen-sensitive LNCaP and androgen-insensitive PC-3 and DU 145 prostate cancer cells was investigated. The authors found that regardless of hormone sensitivity, the growth of prostate cancer cells was significantly and dose- dependently down regulated by iCR. At a concentration between 37.1 and 62.7 μg/ml, iCR caused 50% cell growth inhibition in all cell lines after 72h. Increases in the levels of the apoptosis-related M30 antigen of approximately 1.8-, 5.9-, and 5.3-fold over untreated controls were observed in black cohosh- treated PC-3, DU 145, and LNCaP cells, respectively, with the induction of apoptosis being dose- and time-dependent. Black cohosh extract was therefore shown to kill both androgen-responsive and non- responsive human prostate cancer cells by induction of apoptosis and activation of caspases. This finding suggested that the cells’ hormone responsive status was not a major determinant of the response to the iCR, and indicated that the extract may represent a novel therapeutic approach for the treatment of prostate cancer. Black cohosh can cause some mild side effects such as stomach upset, cramping, headache, rash, a feeling of heaviness, vaginal spotting or bleeding, and weight gain. It is possibly unsafe when used during pregnancy or breast-feeding. There is some concern that black cohosh might worsen existing breast cancer. It should be avoided in hormone-sensitive conditions (like endometriosis, fibroids, ovarian cancer, uterine cancer, and others) and liver diseases. It might also increase the risk of blood clots in people with preexisting conditions like Protein S deficiency. It may interact with drugs like atorvastatin , cisplatin , medications metabolized by the liver, blood thinners, OCPs, etc.

References

1. Grant P. Polycystic ovary syndrome. Available

from:http://www.yourhormones.info/endocrine_conditions/polycystic_ovary_syndrome.aspx.

2. Lee OD. Think androgen deficiency. Am J Mens Health. 2011;5(5):377. doi: 10.1177/1557988311416633.[PubMed] [Cross Ref]

3. Fujita R, Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, et al. Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol. 2005;102(1):107–12. doi: 10.1016/j.jep.2005.05.041. [PubMed] [Cross Ref]

4. Armanini D, Bonanni G, Palermo M. Reduction of serum testosterone in men by licorice. N Engl J Med.1999;341(15):1158. doi: 10.1056/NEJM199910073411515. [PubMed] [Cross Ref]

5. Somjen D, Knoll E, Vaya J, Stern N, Tamir S. Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo. J Steroid Biochem Mol Biol. 2004;91(3):147–55. doi:10.1016/j.jsbmb.2004.04.003. [PubMed] [Cross Ref]

6. Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol. 2001;78(3):291–8. [PubMed]

7. Takeuchi T, Nishii O, Okamura T, Yaginuma T. Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. Am J Chin Med. 991;19(1):73–8. [PubMed]

8. Grant P, Dworakowska D. Tea and Diabetes: the laboratory and the real world. In: Preedy V, editor. Tea in Health & Disease Prevention. 1st ed. Elsevier Academic Press; 2012.

9. Akdogan M, Tamer MN, Cure E, Cure MC, Koroglu BK, Delibas N. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytother Res. 2007;21(5):444–7. doi: 10.1002/ptr.2074. [PubMed] [Cross Ref]

10. Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010;24(2):186–8. doi: 10.1002/ptr.2900. [PubMed] [Cross Ref]

11. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.Ann Intern Med. 2006;145(12):869–79. [PubMed]

12. Fang ZZ, Nian Y, Li W, Wu JJ, Ge GB, Dong PP, et al. Cycloartane triterpenoids from Cimicifuga yunnanensis induce apoptosis of breast cancer cells (MCF7) via p53-dependent mitochondrial signaling pathway.Phytother Res. 2011;25(1):17–24. doi:10.1002/ptr.3222. [PubMed] [Cross Ref]

13. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Apoptosis of human prostate androgen-dependent and – independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18. Anticancer Res. 2005;25(1A):139–47. [PubMed]

14. Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events.Drug Saf. 2005;28(4):319–32. [PubMed]

15. Webster DE, He Y, Chen SN, Pauli GF, Farnsworth NR, Wang ZJ. Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol. 2011;81(1):170–7. doi: 10.1016/j.bcp.2010.09.013.[PMC free article] [PubMed] [Cross Ref]

16. Azadbakht M, Baheddini A, Shorideh S, Naser Zadeh A. Effect of vitex agnus-castus l. leaf and fruit flavonoidal extracts on serum prolactin concentration. J Med Plants. 2005;4(16):56–61.

17. Merz PG, Gorkow C, Schrodter A, Rietbrock S, Sieder C, Loew D, et al. The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes.1996;104(6):447–53. doi: 10.1055/s-0029-1211483. [PubMed] [Cross Ref]

18. Grant NN, Anawalt BD. Male hormonal contraception: an update on research progress. Treat Endocrinol.2002;1(4):217–27. [PubMed]

19. Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93(6):751–6. doi: 10.1111/j.1464-410X.2003.04735.x. [PubMed] [Cross Ref]

20. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database SystRev. 2002;(3):CD001423 doi:10.1002/14651858.CD001423. [PubMed] [Cross Ref]

21. Murugusundram S. Serenoa Repens: Does It have Any Role in the Management of Androgenetic Alopecia? J Cutan Aesthet Surg. 2009;2(1):31–2. doi: 10.4103/0974-2077.53097. [PMC free article] [PubMed] [Cross Ref]

22. Liepa GU, Sengupta A, Karsies D. Polycystic ovary syndrome (PCOS) and other androgen excess-related conditions: can changes in dietary intake make a difference? Nutr Clin Pract. 2008;23(1):63–71. [PubMed]

23. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557–66. doi:10.1056/NEJMoa053085. [PubMed] [Cross Ref]

24. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2008;179(6):2119–25. doi: 10.1016/j.juro.2008.01.094. [PubMed] [Cross Ref]

25. Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia.Ther Adv Urol. 2011;3(4):193–8. doi: 10.1177/1756287211418725. [PMC free article] [PubMed] [Cross Ref]

26. Sosnowska J, Balslev H. American palm ethnomedicine: a meta-analysis. J Ethnobiol Ethnomed. 2009;5:43. doi:

10.1186/1746-4269-5-43. [PMC free article] [PubMed] [Cross Ref]

27. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;(2):CD001423 doi: 10.1002/14651858.CD001423.pub2. [PMC free article][PubMed] [Cross Ref]

28. Grant P, Ramasamy S. The Pituitary Gland & Erectile Dysfunction. In: Grant P, editor. Erectile Dysfunction: Causes, Risk Factors & Management. Nova Publishers; 2012.

29. Magin PJ, Adams J, Heading GS, Pond DC, Smith W. Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients’ experiences and perceptions. J Altern Complement Med. 2006;12(5):451–7. doi: 10.1089/acm.2006.12.451. [PubMed] [Cross Ref]

Real-Time In-Vivo Confocal Scanning Laser Microscopy

The gold standard for diagnosis in dermatology is histopathologic examination of tissue. Although cutaneous biopsies are associated with a relatively low morbidity, there is always a risk for infection, bleeding, and scarring. Biopsies also destroy the site of interest and the dynamic changes over time cannot be observed. Moreover, it consumes time! The search to overcome the drawbacks of the traditional skin biopsy and to provide high resolution images has led to the development of non-invasive techniques such as dermoscopy and in-vivo confocal microscopy.

Confocal scanning laser microscopy(CSLM), often referred as reflectance confocal microscopy, is a novel non-invasive imaging technique that enables the identification of cells and tissues with nearly histologic resolution. The confocal microscope was originally designed by Marvin Minsky (1955), which has further undergone decades of improvisation in structure. With the presently available ones, it is possible to image the skin in vivo, in real time and display on a monitor the 3D morphology and dynamic events. Skin can also be imaged by a confocal microscope in freshly biopsied (in vitro) specimens without processing and staining that is required for routine histopathology. The maximum depth of visualization by CSLM is 200-350µm below the stratum corneum covering the epidermis, papillary dermis and superficial reticular dermis. It allows a horizontal scanning of the imaged tissue, with the advantage of exploring a larger field of view compared with vertical sectioning.

In conventional microscopy, a tissue section is placed on the microscope stage and the entire field of the specimen is simultaneously illuminated by light and visualized. The illumination of other parts of the sample surrounding the point of interest, results in a “background noise,” which compromises the quality of the image.

However, in CSLM, a beam of light (generated by a laser medium) is focused on a small spot inside the tissue through the microscope objective via a dichroic mirror. The mirror is capable of reflecting the light as well as allowing it to pass through. The same objective gathers the reflected light coming back from the tissue, and is projected on a screen. Confocal microscopy overcomes the problem of “background noise” using a small pinhole aperture in a screen that allows only the light emitting from the desired focal spot to pass through. Any light outside of the focal plane (the scattered light) is blocked by the screen. In optical terms, the pinhole is placed in a conjugate focal plane as the tissue specimen (hence the designation “confocal”). A sensitive light detector, such as a photomultiplier tube, on the other side of the pinhole is used to detect the confocal light. (See figure) This technique allows the specimen to be imaged one “point” at a time. Because the sample is not actually sectioned, it is possible to image a “stack” of virtual, confocal image planes that can later be used to make tomographic images, similar to the reconstructions of magnetic resonance imaging or computed tomography scanners in medicine.

Applications of CSLM in dermatology:

  • Microscopic analysis of skin structures (including hairs and nails) and their composition at different anatomic sites.
  • Detection of premalignant changes in pigmented skin conditions.
  • Identification of fungal hyphae and Sarcoptes scabiei mite.
  • Monitoring number and activity of inflammatory cells in diseases like psoriasis, lichen planus etc.
  • Visualizing intradermal tattoo pigments for laser treatment.
  • Defining margins in Mohs surgery.

Limitations of confocal microscopy include the depth of imaging within thick samples and cost compared with conventional microscopes. Nevertheless, technologies for microscopy are promising and are still being improved.

Review Of Topical Lightening Agents

Introduction

Hyperpigmentation occurs when there is an increase in melanin content in the skin. It  can  be  localised  i.e.  limited  to  a  certain  area or it can be diffuse i.e. occurring all over the body. Localised form of hyperpigmentation can happen as a result of injury or inflammation from conditions such as Acne, contact dermatitis, lupus etc known as post inflammatory hyperpigmentation or Melasma. Diffuse generally results from a systemic disease, drug or neoplasm. Localised hyperpigmentation like PIH and melasma can lead to a     lot of psychological distress [1] with skin type IV and above being particularly susceptible [2]. It is not only important to find the cause of pigmentation in order to arrest further progression but it is also important to treat the pigmented lesions. Further prevention should advocate the use of daily sun protection with sunscreen agents and other sun avoidance measures.

Topical Agents

Number of topical agents is used to treat PIH. The most commonly used agent is hydroquinone between 2 to 10% though 2 to 4% of hydroquinone alone or with of tretinoin 0.05 to 0.1% is used [3]. Hydroquinone is a hydroxyphenolic chemical classically used in melasma treatment.

Hydroquinone

Hydroquinone is one of the important agents when treating PIH. It is a phenol compound which inhibits tyrosinase, thereby reducing the conversion of dihydroxyphenylalanine (DOPA) to melanin [4]. In the US, hydroquinone is available over the counter (OTC) at 2% and in a prescription strength from 3% to 10%, although hydroquinone is typically used at 2–4% concentrations [5,6].

Daily concomitant use of a broad-spectrum sunscreen can also be beneficialassunexposurecanhindertheeffectsofhydroquinone, leading
spectrophotometer readings showed statistically significant reductions in melanin content as early as week 4. Similar results were obtained in a previous study [8]. The 5% concentration of hydroquinone may also be compounded with 0.5% ascorbic acid in a low-potency corticosteroid base to increase penetration and reduce irritation, respectively. An improvement in the hyperpigmentation may be noticeable after 4 weeks of therapy but the optimal effect is typically achieved after 6–10 weeks of therapy [9]. Prolonged daily use of 4–5% hydroquinone can lead to a high incidence of irritant reactions particularly when combined with retinoic acid [9].

A triple combination cream in a stabilized formulation, containing 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide, has been demonstrated to be both safe and effective in the treatment  of moderate to severe melasma [6,9-11] and has also been successfully used in the treatment of PIH, although formal clinical studies are needed.

In 1982, the US FDA originally proposed that OTC hydroquinone at 1.5–2% concentrations was generally safe and effective. However, in 2006, the FDA released a statement proposing a ban on all OTC hydroquinone agents and a requirement for any currently marketed hydroquinone product to submit New Drug Application (NDA) or be withdrawn from the market [12]. This change in position was based  on rodent studies, which suggested that oral hydroquinone may be a carcinogen [12]. The FDA has yet to make a final ruling. In light of the controversy surrounding the use of topical hydroquinone, clinicians are looking to other products with depigmenting effects. Mequinol, tretinoin monotherapy, and azelaic acid have also been proven to be effective in the treatment of PIH.

Mequinol

Mequinol (4-hydroxyanisole) is a  derivative  of  hydroquinone  but may cause less skin irritation than its parent  compound.  Mequinol may involve in competitive inhibition of tyrosinase thereby inhibiting  melanin  formation  [13].  An  open-label,  split  face,  non-


to repigmentation. Antioxidants such as 0.5% ascorbic acid (vitamin C) and retinoid as well as a-hydroxy acids are used as additives to increase penetration and enhance efficacy. Cook- Bolden and Hamilton [7] conducted a 12-week, open-label study of microencapsulated 4% hydroquinone and 0.15% retinol with antioxidants in the treatment of 21 patients (17 PIH, 4 melasma). Significant decreases in lesion size, pigmentation, and disease severity were noted as early as 4 weeks after initiating treatment and remained significantly decreased throughout the study (all p<0.032). The majority of patients (63%) experienced either marked improvement (75% overall improvement) or complete clearing  (95%  or  greater  overall  improvement),  and      reflectance

spectrophotometer readings showed statistically significant reductions in melanin content as early as week 4. Similar results were obtained in a previous study [8]. The 5% concentration of hydroquinone may also be compounded with 0.5% ascorbic acid in a low-potency corticosteroid base to increase penetration and reduce irritation, respectively. An improvement in the hyperpigmentation may be noticeable after 4 weeks of therapy but the optimal effect is typically achieved after 6–10 weeks of therapy [9]. Prolonged daily use of 4–5% hydroquinone can lead to a high incidence of irritant reactions particularly when combined with retinoic acid [9].

A triple combination cream in a stabilized formulation, containing 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide, has been demonstrated to be both safe and effective in the treatment  of moderate to severe melasma [6,9-11] and has also been successfully used in the treatment of PIH, although formal clinical studies are needed.

In 1982, the US FDA originally proposed that OTC hydroquinone at 1.5–2% concentrations was generally safe and effective. However, in 2006, the FDA released a statement proposing a ban on all OTC hydroquinone agents and a requirement for any currently marketed hydroquinone product to submit New Drug Application (NDA) or be withdrawn from the market [12]. This change in position was based  on rodent studies, which suggested that oral hydroquinone may be a carcinogen [12]. The FDA has yet to make a final ruling. In light of the controversy surrounding the use of topical hydroquinone, clinicians are looking to other products with depigmenting effects. Mequinol, tretinoin monotherapy, and azelaic acid have also been proven to be effective in the treatment of PIH.

Mequinol

Mequinol (4-hydroxyanisole) is a  derivative  of  hydroquinone  but may cause less skin irritation than its parent  compound.  Mequinol may involve in competitive inhibition of tyrosinase thereby inhibiting  melanin  formation  [13].  An  open-label,  split  face,  non- inferiority, comparison study of 2% mequinol/0.01% tretinoin versus 4% hydroquinone cream was  conducted  in  61  patients  with  mild to moderate facial PIH [14]. Patients applied 2% mequinol/0.01% tretinoin to one side of the face and 4% hydroquinone to the contra lateral side for 12 weeks. The mequinol/tretinoin solution was found to be non-inferior to the hydroquinone cream in the treatment of PIH as 81% of mequinol/tretinoin-treated and 85% of hydroquinone-treated patient’s experienced clinical success.

*Corresponding author: Dr. Shuba Dharmana, Le’Jeune Medspa, 52, Vittal Mallya Road, 1st floor, Bangalore, 560 001, India, Tel: +91 9845104890; E-mail: [email protected]

Received:  September  05,  2014;  Accepted:  October  20,  2014;    Published:

October 24, 2014

Citation: Dharmana S (2014) Review of Topical Lightening Agents. Pigmentary Disorders 1:145. doi: 10.4172/JPD.1000145

Copyright: © 2014 Dharmana S. The terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Retinoids

Tretinoin (all-trans retinoic acid), a vitamin A analog, used to  treat hyperpigmentation of photo aged skin, post inflammatory hyperpigmentation, and melasma. Tretinoin 0.1% has been used to successfully treat melasma in Black patients; improvements of up to 73% were seen after 40 weeks of treatment [5]. Erythema and peeling in the area of application are adverse effects of tretinoin 0.05 to 0.1%; post inflammatory hyperpigmentation can also occur.

Concentrations range from 0.01% to 0.1%. However, irritant dermatitis can be a frequent adverse effect, and caution should be used when prescribing higher concentrations of tretinoin in darker skin types, since the irritation can lead to further PIH. To determine the safety  and  efficacy  of  0.1%  tretinoin  in  the  treatment of PIH, a randomized, double-blind, vehicle-controlled clinical trial was conducted in 54 Black patients [5]. Patients applied either tretinoin   or vehicle cream to the face, arms, or both areas daily for 40 weeks.  At the study endpoint, the PIH lesions of the tretinoin-treated group were significantly lighter than those of the vehicle-treated group as assessed by clinical (p<0.001) and colorimetric (p=0.05) examinations. However, it is important to note that patients treated with tretinoin experienced minimal lightening of normal skin and 50% of these patients also developed retinoid dermatitis. It is possible to reduce  this irritation by reducing dose and titrating to higher doses gradually or by using cream based formulations [15] or even diluting it with a moisturizer.

Other retinoid compounds are also available including isotretinoin, adapalene, and tazarotene. Isotretinoin is available in both oral and topical formulations and is widely used in the treatment of acne.

Azelaic acid

Topical azelaic acid 15 to 20% can be as efficacious as hydroquinone, but is less of an irritant.

Azelaic acid is a dicarboxylic acid isolated from Pityrosporum ovale, the organism responsible for pityriasis versia color [9].

Studies have shown that 20% azelaic acid cream produces significantly greater decreases in pigmentary intensity than the vehicle [16] and, when combined with 15–20% glycolic acid, is as effective as 4% hydroquinone in the treatment of facial hyperpigmentation including melasma and PIH [17]. Azelaic acid is generally well tolerated with only mild adverse effects reported, such as pruritus, transient erythema, scaling, and irritation, which disappear in a few weeks [18].

Kojic Acid

Kojic acid has recently been used as a 2% cream, alone or in combination with glycolic acid or hydroquinone, due to its inhibitory action on tyrosinase. In a comparative study in Chinese women with epidermal melasma, half of the face was treated with kojic acid 2% gel plus glycolic acid 10% and hydroquinone 2%, and the other half of  the face with just glycolic acid 10% and hydroquinone 2% [19]. Better results were obtained on the half of the face treated with the cream

including kojic acid.

A common adverse effect with kojic acid use is contact dermatitis [20,21]. Although kojic acid had been widely used in skin care products in Japan, more recent clinical studies conducted there have demonstrated its highly sensitizing potential [22]. Kojic acid has also been recently banned from the Japanese market over mutagenicity concerns.

Arbutin

Arbutin works by inhibiting tyrosinase activity as well as melanosome maturation, and its efficacy is concentration dependent but higher concentrations can lead to a paradoxical hyperpigmentation [23]. a-Arbutin and deoxyarbutin are both synthetic forms with greater tyrosinase inhibition than the original arbutin [24,25]. Clinical studies have demonstrated that 3% deoxyarbutin is effective in lightening solar lentigines in light-skinned patients [26]; however, there are no data on its efficacy for PIH.

Niacinamide

Niacinamide is the water-soluble, physiologically active derivative of niacin (vitamin B3). Topical niacinamide has been used in the treatment of acne but studies now suggest that there may be a role    for niacinamide in the treatment of pigmentary disorders. Hakozaki   et al. [27] showed through in vitro studies that niacinamide decreases melanosome transfer by 35–68% without inhibiting tyrosinase activity or cell proliferation. Research also suggests that niacinamide may decrease melanogenesis by interfering with the interaction between keratinocytes and melanocytes but not through a directly inhibitory effect on melanocytes. Two to five percent niacinamide has proven    to be an effective lightening agent for patients with melasma or UV induced hyperpigmentation [27-29]; however, studies are needed to determine its safety and efficacy in the treatment of PIH.

N-Acetyl Glucosamine

Multiple, double-blind, controlled, clinical trials  demonstrated  the clear benefit of 2% N-acetyl glucosamine in the treatment of hyperpigmentation secondary to sun exposure [28,30] but none secondary to inflammatory causes.

Ascorbic Acid (Vitamin C)

Ascorbic acid is a depigmenting agent that suppresses melanin synthesis by its antioxidant properties, Ascorbic acid is not a very effective skin lightening agent when used as monotherapy; however, 5–10% ascorbic acid is still frequently formulated in combination with other depigmenting agents such as hydroquinone given its excellent safety profile [31]. Further studies are needed to determine the utility of ascorbic acid in the management of PIH. However, ascorbic acid has shown some efficacy as combination therapy for photo aging and melasma.

Licorice Extract

Licorice extract is a very common component of depigmenting cosmetic products sold worldwide. There are several active agents in licorice extract including glabridin and licochalcone A, which have both been shown to inhibit tyrosinase activity [32,33]. In addition, glabridin exhibits anti-inflammatory properties. Liquiritin, another active ingredient of licorice extract, does not inhibit tyrosinase activity but causes depigmentation by melanin dispersion [34]. There are very few clinical studies with licorice extract; however, liquiritin 1 g/day has

been shown to be effective treatment for melasma, although no patients with PIH were included in the study.

Soy

Soy extracts are commonly used in cosmetic skin moisturizers for their skin-lightening properties [31] and a manufacturer’s study has demonstrated improvement of certain dyschromias including PIH with the use of a daily SPF 15 soy moisturizer. Whole soy extract has also shown some efficacy in the treatment of PIH secondary to acne when formulated with salicylic acid and retinol.

Chemical Peels

One of the most common indications for chemical peeling is dyschromias such as PIH. Chemical peels used alone or in combination with lightening agents can be very efficacious. Typically, superficial chemical peels have been studied as therapy for PIH. These peels can be used in all skin types, and are commonly used in patients with darker skin tones because they are generally well tolerated with proven results. Care should be taken in selecting the specific chemical peel to avoid possible irritation, which can worsen PIH. Patients should also practice sun avoidance and wear sunscreen to avoid PIH after having received a chemical peel.

Chemical peeling with glycolic acid utilizes strengths ranging from 20% to 70% and requires neutralization with water or sodium bicarbonate to terminate the peel. Burns et al. [35] conducted a study of 16 African American patients with facial PIH in which the control group was treated with 2% hydroquinone/10% glycolic acid gel and 0.05%tretinoin and the peel group was treated with the same topical regimen plus a series of six glycolic acid peels (50–68%) at 3-week intervals. Significant clinical improvement was noted compared to baseline in the peel group using the Hyperpigmentation Area and Severity Index (HASI) (p<0.02); however,  the  difference  between the two treatment groups was close to but did not reach statistical significance. The peel group also experienced a more rapid and greater improvement by colorimetric analysis but results were of borderline significance (p<0.09). The authors also reported a greater lightening of normal pigmentation in the peel group.

Superficial salicylic acid peels typically utilize strengths ranging from 20% to 30%. A clinical study was conducted using salicylic acid peels in 24 Korean patients with PIH secondary to acne [36]. Salicylic acid (30%) peels were performed every 2 weeks for 3 months. Although the level of lightness from baseline to the first post-peel period was significant (p<0.02) by colorimetric analysis, final levels did not reach statistical significance. However, colorimetric analysis did show a highly significant reduction in erythema (p<0.0001), and clinical improvement was noted in greasiness, dryness, scaliness, and erythema at the study endpoint.

Laser Therapy

There are a number of different lasers and light sources currently available that can also be effective for PIH. Due to the wide absorption spectrum of melanin, which ranges from 250 to 1200 nm, melanin  can be targeted specifically by all visible light and near-infrared dermatologic lasers currently in use [37].

Lasers with shorter wavelengths are not optimal for treatment     in darker-skinned patients since the individual’s normal epidermal melanin is also targeted at these wavelengths. The absorption coefficient of melanin decreases exponentially as the wavelength increases [38]. Therefore, lasers generating wavelengths that are   less

efficiently absorbed by endogenous melanin, such as the 1064 nm QS neodymium: yttrium-aluminum-garnet (Nd:YAG) laser can provide a greater margin of safety while still allowing the laser surgeon to achieve satisfactory results in darker-skinned individuals.

Emerging Therapies

As there is more demand for new depigmenting agents, A recent, randomized, double-blind, vehicle-controlled clinical trial showed that 2% undecylenoyl phenylalanine effectively treats solar lentigines [39], and a published case-report explains how topical 5% methimazole  was successfully used to treat PIH secondary to a chemical burn [40]. Dioic acid has been compared with hydroquinone in the treatment of melasma, showing it to be a possible treatment alternative [41], and aloesin has been shown in studies to suppress pigmentation induced  by UV radiation [42]. Other  agents  that  require  further  research  and development include 4-(1-phenylethyl)1,3-benzenediol, paper mulberry, ellagic acid, quinolines, piperlonguminine, luteolin, and calycosin [20].

Conclusion

Hyperpigmented disorders of the skin pose a significant medical and  esthetic  problem  for  individuals  with  any  skin  complexion.  A variety of topical and systemic agents have been employed in the treatment of these disorders. Many studies are conducted and being conducting however more studies are needed to elucidate the exact role of most of the agents used for depigmentation. As the cosmetic industry is growing faster, more agents are expected to be discovered. Simultaneously market/consumers are looking for alternatives for prescribed treatments for skin lightening and inclining towards  natural/ neutral agents.

References

  1. Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman SR (2008) Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol 7: 164-168.
  2. Rossi AM, Perez MI (2011) Treatment of hyperpigmentation. Facial Plast Surg Clin North Am 19: 313-324.
  3. Pérez-Bernal A, Muñoz-Pérez MA (2000) Management of Facial Hyperpigmentation. Am J Clin Dermatol 1: 261-268.
  4. Palumbo A, d’Ischia M, Misuraca G, Prota G (1991) Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta 1073: 85-90.
  5. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, et al. (1994) Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol 130: 727-733.
  6. Lacz NL, Vafaie J, Kihiczak NI, Schwartz RA (2004) Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol 43: 362- 365.
  7. Cook-Bolden FE, Hamilton SF (2008) An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis 81: 365-371.
  8. Grimes PE (2004) A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 74: 362-368.
  9. Jimbow K, Minamitsuji Y (2001) Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther 14: 35-45.
  10. Kligman AM, Willis I (1975) A new formula for depigmenting human skin. Arch Dermatol 111: 40-48.
  11. Chan R, Park KC, Lee MH, Lee ES, Chang SE, et al. (2008) A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 159: 697-703.
  12. Levitt J (2007) The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol 57: 854-872.
  13. Draelos ZD (2006) The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol 5: 239-244.
  14. Taylor SC, Callender VD (2006) A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinoin 0.01% vs hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation. J Am Acad Dermatol 54: AB194.
  15. Callender VD (2004) Acne in ethnic skin: special considerations for therapy. Dermatol Ther 17: 184-195.
  16. Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S (1998) Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 20: 945-959.
  17. Kakita LS, Lowe NJ (1998) Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther 20: 960-970.
  18. Ortonne JP, Passeron T (2005) Melanin pigmentary disorders: treatment update. Dermatol Clin 23: 209-226.
  19. Lim JT (1999) Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 25: 282-284.
  20. Grimes PE (2009) Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg 28: 77-85.
  21. Serra-Baldrich E, Tribó MJ, Camarasa JG (1998) Allergic contact dermatitis from kojic acid. Contact Dermatitis 39: 86-87.
  22. Nakagawa M, Kawai K, Kawai K (1995) Contact allergy to kojic acid in skin care products. Contact Dermatitis 32: 9-13.
  23. Maeda K, Fukuda M (1996) Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther 276: 765-769.
  24. Funayama M1, Arakawa H, Yamamoto R, Nishino T, Shin T, et al. (1995) Effects of alpha- and beta-arbutin on activity of tyrosinases from mushroom and mouse melanoma. Biosci Biotechnol Biochem 59: 143-144.
  25. Boissy RE, Visscher M, DeLong MA (2005) DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 14: 601-608.
  26. Boissy RE1, Visscher M, DeLong MA (2005) DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 14: 601-608.
  27. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, et al. (2002) The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 147: 20-31.
  28. Kimball AB, Kaczvinsky JR, Li J, Robinson LR, Matts PJ, et al. (2010) Reduction in the appearance of facial hyperpigmentation after use of moisturizers with    a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, doubleblind, vehicle-controlled trial. Br J Dermatol 162: 435-441.
  29. Bissett DL, Miyamoto K, Sun P, Li J, Berge CA (2004) Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci 26: 231-238.
  30. Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki T, et al. (2007) Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine. J Cosmet Dermatol 6: 20-26.
  31. Draelos ZD (2007) Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 20: 308-313.
  32. Fu B, Li H, Wang X, Lee FS, Cui S (2005) Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem 53: 7408-7414.
  33. Yokota T, Nishio H, Kubota Y, Mizoguchi M (1998) The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 11: 355-361.
  34. Amer M, Metwalli M (2000) Topical liquiritin improves melasma. Int J Dermatol 39: 299-301.
  35. Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, et al. (1997) Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg 23: 171-174.
  36. Ahn HH, Kim IH (2006) Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg 32: 372-375.
  37. Tanzi EL, Alster TS (2004) Cutaneous laser surgery in darker skin phototypes. Cutis 73: 21-24, 27-30.
  38. Alster TS, Tanzi EL (2003) Laser surgery in dark skin. Skinmed 2: 80-85.
  39. Katoulis AC1, Alevizou A, Bozi E, Makris M, Zafeiraki A, et al. (2010) A randomized, double-blind, vehiclecontrolled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol 35: 473-476.
  40. Kasraee B, Handjani F, Parhizgar A, Omrani GR, Fallahi MR, et al. (2005) Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. Dermatology 211: 360-362.
  41. Tirado-Sánchez A, Santamaría-Román A, Ponce-Olivera RM (2009) Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol 48: 893-895.
  42. Choi S, Lee SK, Kim JE, Chung MH, Park YI (2002) Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol 27: 513-515.

Procedures for Rejuvenation of Eyes: The Aesthetic Centre of Face

Periorbital anatomy: The skin around the eyes is thinnest in the body with minimal subcutaneous fat. A thorough knowledge of anatomy is required for performing procedures on this sensitive area so as to avoid complications.

Causes of dark circles:

There are several factors:-

a.Heredity : Dark circles are inherited trait.The skin around the eyes is very thin so when blood passes through the veins close to the surface of thin skin it gives bluish tint.

b.Excessive exposure to sun : Causes the thin skin around the eyes to become more thinner and fastens the wrinkle formation. Sun exposure also increases production of melanin and increases the dilatation of blood vessels.

c.Lack of sleep and stress: Causes accumulation of hemoglobin and hemosiderin induced pigmentation

d.Anaemia and lack of balance diet: Contributes to the discoloration of area around the eyes.

e.Age : Loss of collagen leads to thinning of skin around the eyes

f. Extension of pigmentary demarcation lines.

g . Other factors : Smoking , Alcohol, Atopic dermatitis, Acute illness can lead to dark circles.

Causes of Puffiness:

a.Heredity

b.Lack of sleep which leads to poor blood circulation

c.Fluid retention :Occurs due to increase of sodium and caffeine intake and less of water intake

d.Ageing

e.Illness : Thyroid disorders, nephropathies, cardiopathies and pnemopathies

Effects of Ageing:

q Pseudo herniation of post septal fat

q Increase in height and width of bony orbit

q Crows feet

q Increase in height and width of bony orbit

q Tear Trough

Medical Therapy

Topical Agents to reduce periorbital hyperpigmentation:

·       Hydroquinone

·       Retinoic acid – 0.01% to 0.1 %

·        Vitamin C, E, K

·       Hydroxy acids

·       Azelaic acid

·       Kojic Acid

·       Arbutin

·       Licorice

·       Sabi white

·       Cosmetic Concealers

Oral Treatment

·       Iron supplements

·       Antioxidants

·       Tranexemic acid

·       Retinoids

·       Multivitamins

Procedural Therapy:

Chemical Peels :

Involve the application of a chemical exfoliating agent to the skin resulting in controlled destruction of the superficial layers of the skin to the required depth , followed by subsequent repair and regeneration .

Various Peeling agents which are available to reduce periorbital melanosis:

Glycolic acid: It is keratolytic and stimulates collagen production

Lactic acid: It is keratolytic and has moisturising effect

Kojic acid : Suppreses the tyrosinase activity

Arginine peels: It increases the elasticity of skin

Ferulic acid : It has antioxidant action

Combination peels: Multiple peeling agents complement their synergistic activity.

6 to 8 sittings of peeling can be done with a gap 15 days

Microneedling : Dermarollers of 0.25 and 0.5mm are available for under eye area

Mechanism of action: Needles create microchannels which increases the delivery of the drug . These substances have antioxidant, anti-inflammatory,depigmenting and vasoprotective effect. It also stimulates the collagen production and also increases the blood supply to the skin.

Drugs which can be used :

·       Glutathione

·       Kojic acid

·       Lactic acid

·       Ascorbic acid

·       Tranexemic acid

·       Hyaluronic acid

Treatment protocol : 4 to 6 sessions one month apart can be done

Lasers : Pigment specific lasers and pigment non-specific lasers can be used for periorbital rejuvenation. Nowadays Q-switched Nd:YAG laser is   safely used  to lighten the pigmentation around the eyes, it is popoularly used in treatment of facial pigmentation.The laser light disperse the pigment cells within the skin ,which leads to reduction of dark circles.

Things to consider :

·       Proper protection of eyes.

·       Internal metal  eye shield mandatory.

·       There may be downtime

·       Use of sunscreen post laser

·       Repeated sessions and maintainence for best results

Jet Peel Technology:The area around the eyes is treated with normal saline under pressure through fine nozzles. It enhances the lymphatic drainage which helps in reduction of puffiness . Lightening agents,vitamins and antiaging agents can be infused with this technology. Chemical peels done after jet peel have much better results than used alone.

PRP( Platelet Rich Plasma therapy): Doing PRP around the eyes helps in collagen and elastin generation which leads helps in wrinkle reduction and also increases the taughtness of the skin.

Neurotoxins: Botulinum toxin  is a protein produced by the anaerobic bacterium Clostridium Botulinum which helps in reduction of wrinkles around the eyes and for brow lift.

When injected intramuscularly at therapeutic dose it leads to partial chemical denervation of muscle resulting in localised reduction in muscular activity.The anatomy of the muscles of facial expression is complex, overlapping , interdigitating and variable hence a thorough knowledge of the muscles of facial expression is important.

Hyaluronic acid fillers: It helps in reduction of tear trough.Product  is placed pre periosteally, anterior to inferior orbital rim . After injecting the hyaluronic acid gel binds water and adds to the volume of tissue . As it hydrates the skin the eyes look fresher post procedure hence it is becoming a popular procedure . Thorough knowledge of periorbital anatomy  and proper technique of injection is required to avoid complications.

Radiofrequency Skin tightening treatment: Radiofrequency does not use laser or light technology hence it overcomes light based disadvantages . It offers enhanced tissue penetration independent of skin colour, causing no or minimal damage to epidermis. Radiofrequency delivers non-specific heat to its target tissues, which results in collagen production .

Thread Lift: PDO threads are gently inserted under the skin with fine needle.The threads create a supportive mesh to deliver a lifting effect and while also smoothing away fine lines and wrinkles. Threads also encourage the skin to produce new collagen and elastin.

Treatment options available depending on symptoms:

Conclusion:It is evident that many treatment options are available for rejuvenation of eyes. Proper patient selection and severity of symptoms is important to determine the best therapeutic option. The most frustating aspect of this concern is limited response to treatments. The key to successful treatment is to target the primary cause and maintenance  of newly rejuvenated skin through sun protection ,a good skin care regime are important to prolong clinical results  .

Refrences:

Malakar S , Lahiri K , Banerjee U , Mondal S , sarangi S ,. Periorbital melanosis is an extension of pigmentary demarcation line – F on face . Indian J Dermatol Venereol leprol . 2007 Sep- Oct ; 73( 5 ) : 3235.

Hirmand H . Anatomy and non surgical correction of the tear trough deformity . Plast Reconstr Surg . 2010 Feb ; 125 ( 2 ):699-708 .

Roh MR , Chung KY . Infraorbital dark circles : definition , causes , and treatment options . Dermatol surg 2009 Aug ; 35 (8) : 1163-7 .

Elsaie ML. Cutaneous remodeling and photorejuvenation using radiofrequency devices. Indian J Dermatol 2009; 54(3): 201–5

Friedman DJ, Gilead LT. The use of hybrid radiofrequency device for the treatment of rhytides and lax skin. Dermatol Surg 2007; 33(5): 543– 1

Doddaballapur S . Microneedling with dermaroller . J Cutan Aesthet Surg . 2009 ; 2 : 110-1 .